Immunomodulatory therapies in sepsis

Area of Science:

• Critical care medicine
• Immunology
• Pathophysiology of sepsis

Background:

• Sepsis involves a dysregulated inflammatory response, including hyperinflammation and anti-inflammatory phases.
• Previous attempts to treat sepsis by downregulating inflammatory mediators have failed, potentially due to a lack of precise immune monitoring.
• Sepsis exhibits a biphasic immune pattern, progressing from hyperinflammation to a hypoinflammatory state characterized by monocytic deactivation (immunoparalysis).

Purpose of the Study:

• To investigate the biphasic immune response in sepsis.
• To evaluate the immunoregulatory effects of Interferon gamma-1b in septic patients with immunoparalysis.
• To highlight the importance of immune status monitoring for targeted sepsis intervention.

Main Methods:

• Observation of biphasic immunological patterns in sepsis.
• Administration of Interferon gamma-1b to septic patients with compensatory anti-inflammatory response syndrome.
• Monitoring of HLA-DR expression and cytokine secretion by monocytes.

Main Results:

• Sepsis demonstrates an early hyperinflammatory phase followed by an anti-inflammatory phase, potentially leading to immunoparalysis.
• Interferon gamma-1b treatment restored HLA-DR expression on monocytes.
• Interferon gamma-1b reestablished the monocytes' ability to secrete cytokines like TNF-alpha.

Conclusions:

• Sepsis involves complex immune dysregulation with distinct hyperinflammatory and hypoinflammatory phases.
• Targeted immunomodulation, guided by precise immune monitoring, holds promise for improving sepsis treatment outcomes.
• Interferon gamma-1b shows potential as an immunoregulatory agent in septic patients with immunoparalysis.